These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 20622257)

  • 41. Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia.
    Scaglione F; Esposito S; Leone S; Lucini V; Pannacci M; Ma L; Drusano GL
    Eur Respir J; 2009 Aug; 34(2):394-400. PubMed ID: 19213786
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing.
    Bland CM; Pai MP; Lodise TP
    Pharmacotherapy; 2018 Dec; 38(12):1229-1238. PubMed ID: 30403305
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Rational empiric antibiotic therapy of nosocomial pneumonia].
    Barczyk A; Pierzchała W
    Wiad Lek; 1999; 52(11-12):591-6. PubMed ID: 10745697
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Duration and cessation of antimicrobial treatment.
    File TM
    J Hosp Med; 2012; 7 Suppl 1():S22-33. PubMed ID: 23677632
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Management of complicated urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Hawboldt J; Brooks A
    Postgrad Med; 2010 Nov; 122(6):7-15. PubMed ID: 21084776
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Suboptimal aminoglycoside dosing in critically ill patients.
    Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
    Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms.
    Niederman MS
    Clin Infect Dis; 2006 Jan; 42 Suppl 2():S72-81. PubMed ID: 16355320
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimal use of fluoroquinolones in the intensive care unit setting.
    Rotschafer JC; Ullman MA; Sullivan CJ
    Crit Care Clin; 2011 Jan; 27(1):95-106. PubMed ID: 21144988
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Empiric antibiotic selection strategies for healthcare-associated pneumonia, intra-abdominal infections, and catheter-associated bacteremia.
    Snydman DR
    J Hosp Med; 2012; 7 Suppl 1():S2-S12. PubMed ID: 23737334
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Empiric antibiotic selection strategies for healthcare-associated pneumonia, intra-abdominal infections, and catheter-associated bacteremia.
    Snydman DR
    J Hosp Med; 2012; 7 Suppl 1():S2-12. PubMed ID: 23677631
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions.
    Lipš M; Siller M; Strojil J; Urbánek K; Balík M; Suchánková H
    Int J Antimicrob Agents; 2014 Oct; 44(4):358-62. PubMed ID: 25216543
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit.
    Xu Y; Jin L; Liu N; Luo X; Dong D; Tang J; Wang Y; You Y; Liu Y; Chen M; Yu Z; Hao Y; Gu Q
    Int J Infect Dis; 2019 May; 82():79-85. PubMed ID: 30878630
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling.
    Nicolau DP
    J Infect Chemother; 2003 Dec; 9(4):292-6. PubMed ID: 14691648
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetic analysis of doripenem in elderly patients with nosocomial pneumonia.
    Harada M; Inui N; Suda T; Nakamura Y; Wajima T; Matsuo Y; Chida K
    Int J Antimicrob Agents; 2013 Aug; 42(2):149-54. PubMed ID: 23684002
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria.
    Kashuba AD; Nafziger AN; Drusano GL; Bertino JS
    Antimicrob Agents Chemother; 1999 Mar; 43(3):623-9. PubMed ID: 10049277
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Nosocomial pneumonia].
    Ewig S; Walger P; Vetter H
    Ther Umsch; 2001 Oct; 58(10):609-13. PubMed ID: 11695092
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Probiotics in the intensive care unit.
    Morrow LE; Gogineni V; Malesker MA
    Nutr Clin Pract; 2012 Apr; 27(2):235-41. PubMed ID: 22473797
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant Acinetobacter?
    Cooper TW; Pass SE; Brouse SD; Hall RG
    Ann Pharmacother; 2011 Feb; 45(2):229-40. PubMed ID: 21304038
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antibiotic dosing for multidrug-resistant pathogen pneumonia.
    Abdul-Aziz MH; Lipman J; Roberts JA
    Curr Opin Infect Dis; 2017 Apr; 30(2):231-239. PubMed ID: 28030371
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro bacterial isolate susceptibility to empirically selected antimicrobials in 111 dogs with bacterial pneumonia.
    Proulx A; Hume DZ; Drobatz KJ; Reineke EL
    J Vet Emerg Crit Care (San Antonio); 2014; 24(2):194-200. PubMed ID: 24382329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.